|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Coagulation Factors
La Merie, Jan 2011, Pages: 139
The present Competitive Intelligence Report about Coagulation Factors provides a competitor evaluation in the field of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of January 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Global sales of the five major recombinant products of coagulation factors VIII, IX and VIIa in 2009 were US$ 5.5 bln. This attractive market size and the soon beginning expiration of basic patents stimulated established hemophilia product companies as well as companies with new technologies to enter the race for next generation systemic coagulation factor products. In fact, projects are rapidly progressing in clinical trials and the field is expected to become very competitive.
Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and plasma-derivd products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.
The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific R&D pipelines of coagulation factors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Coagulation Factors 2010 - The Portfolio Aspect as Decisive Force: A Competitive Landscape and R&D Pipeline Analysis of Hemostasis Proteins
Coagulation Factors 2011 - Who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis
Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors
Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline
Hemophilia - Pipeline Assessment and Market Forecasts to 2017
Textbook of Hemophilia, 2nd Edition
Biosimilars and Biobetters: Positioning for a New Market
Protein Drugs - Global Strategic Business Report
Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects
|
|
|
|
